Clinical trials: Neurofilaments Light Chains
Hydrocephalus, Normal Pressure, Biochemical Lesions Head Region
Role of Brain Specific Biomarkers in Hydrocephalus
Normal pressure hydrocephalus (NPH) is a neurodegenerative disease of unclear etiology characterized by a clinical trias named after the neurosurgeon Hakim.
- Conditions
- Hydrocephalus, Normal Pressure, Biochemical Lesions Head Region, Brain Damage
- Trial name
- NCT06083233
- Testing
- Lumbar puncture, External lumbar drainage, Ventriculo-peritoneal shunt placement
- Where
- Czechia
- Volunteers
- 32 people
- Sponsor
- University Hospital Hradec Kralove
Multiple Sclerosis
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
Multiple sclerosis (MS) is an immune-mediated disease characterized primarily by inflammatory demyelinating lesions in the central nervous system (CNS), with the white matter being predominantly affected.
- Trial name
- NCT07353216
- Testing
- Ofatumumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT05156281
- Testing
- Remibrutinib, Teriflunomide
- Where
- 223 sites in United States, Argentina and 25 more
- Volunteers
- 1,007 people
- Sponsor
- Novartis Pharmaceuticals
Cardiac Arrest (CA), Intensive Care Unit (ICU) Admission
Kinetics and Prognostic Value of NeuroFilament Light in Post-cardiac Arrest: A Prospective Multicenter Study
The purpose of this study is to assess the prognostic value of absolute value and kinetic of neurofilament light chain (NFL) collected at different time points (at admission, 12h, 24h, 48h, 72h, 96h, and day 7 after ICU…
- Conditions
- Cardiac Arrest (CA), Intensive Care Unit (ICU) Admission, Return of Spontaneous Circulation, Comatose
- Trial name
- CINEFIL (NCT07760636)
- Testing
- Value of neurofilament light chain (NFL) at different time points
- Where
- France
- Volunteers
- 270 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Behçet
Neurofilament Light Chain as a Potential Marker in Behcet's Disease
To determine the role of neurofilament light chain in Behçet's disease with or without neurological affection and its relation to neurological manifestation (either peripheral or central ).
- Trial name
- NCT06060275
- Testing
- serum sample and nerve conduction study and cerebrospinal fluid study
- Volunteers
- 60 people
- Sponsor
- Assiut University
Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder, Dementia, Neurodegenerative Disease
- Trial name
- DIV-AD (NCT07521722)
- Where
- Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Carotid Artery Stenosis, Carotid Artery Stenosis Asymptomatic
The VANGAS-Trial. The Value of Neurofilament Light Chain and Glial Fibrillary Acid Protein in the Blood of Patients With Asymptomatic Carotid Artery Stenosis
Stroke is the second leading cause of death and the third leading cause of disability worldwide. The cause is usually either a blockage or a severe narrowing of a cerebral artery.
- Conditions
- Carotid Artery Stenosis, Carotid Artery Stenosis Asymptomatic, Carotid Artery Diseases, Carotid Artery Plaque
- Trial name
- VANGAS (NCT06211725)
- Where
- 2 sites in Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Sclerosis
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).
- Trial name
- SurfSubQ (NCT06780150)
- Testing
- Ocrelizumab
- Where
- 93 sites in Germany, Switzerland
- Volunteers
- 842 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Neurofilament Light Chain
To Study the Pathophysiological Features of Multiple Sclerosis
Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system1, whose demyelination is the pathological hallmark.
- Conditions
- Multiple Sclerosis, Neurofilament Light Chain, Glial Fibrillary Acidic Protein
- Trial name
- NCT04242056
- Testing
- 18F-PM-PBB3
- Volunteers
- 38 people
- Sponsor
- Chang Gung Memorial Hospital
Multiple Sclerosis
Neurofilaments for NEDA Assessing in MS
Goal is to evaluate the achievement of biological NEDA as demonstrated by a drop in neurofilament levels in MS patients commencing Alemtuzumab therapy as part of their MS management.
- Trial name
- NCT03250169
- Testing
- Alemtuzumab
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- Queen Mary University of London
Sleep Apnea, Obstructive
Biological and Cognitive Marker of Neurodegeneration in Obstructive Sleep Apnea Patients
The goal of this observational study is to investigate biomarkers and neurocognitive markers of neurodegenerative processes in obstructive sleep apnea patients.
- Trial name
- NCT06167369
- Where
- Germany
- Volunteers
- 136 people
- Sponsor
- Technische Universität Dresden
Amyotrophic Lateral Sclerosis (ALS)
Developing New Ways to Detect Respiratory Impairment Early in ALS
The goal of this observational study is to develop new ways to detect early changes associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
- Trial name
- NCT07844590
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Multiple Sclerosis, Exercise
Impact of Exercise Training on Serum Neurofilament Light Chain (NfL), Brain Volumetry, and Functional Outcomes in Multiple Sclerosis
This single-blind, randomized controlled trial will employ a two-arm parallel design (exercise group vs. control group) with a 12-week intervention period.
- Conditions
- Multiple Sclerosis, Exercise, Neurofilament Light Chain
- Trial name
- NCT07520812
- Testing
- Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people
- Sponsor
- Firat University
Relapsing Remitting Multiple Sclerosis (RRMS)
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context…
- Trial name
- ELIOS (NCT06733922)
- Testing
- ETNATM-ProgMS
- Where
- 14 sites in Canada
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
NMOSD
Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is a nationwide observational study looking at how ravulizumab, a complement C5 inhibitor, affects blood biomarkers o sNfL and sGFAP in people with AQP4-antibody positive NMOSD.
- Trial name
- NCT06903130
- Testing
- Blood samples for sNfL and sGFAP levels
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- National and Kapodistrian University of Athens
Persistent Post-concussive Syndrome, Concussion Post Syndrome
Hyperbaric Oxygen Effects on Persistent Post-concussive Symptoms
Persistent post-concussive symptoms (PPCS) are a source of significant burden among a subset of patients with concussion with prevalence rates previously reported between 11 - 82% based on timing of assessment, diagnostic…
- Trial name
- HOINPCS (NCT05173818)
- Testing
- Hyperbaric oxygen at 1.5 ATA
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Essentia Health
Down Syndrome
Non-Invasive Brain Stimulation to Improve Language in Down Syndrome.
Down syndrome (DS) is associated with cognitive deficits, caused by alterations in neuroplasticity and synaptic transmission. Non-invasive brain stimulation techniques, such as transcranial direct current stimulation (tDCS), can…
- Trial name
- NCT07044804
- Testing
- Active Group (Active Anodal tDCS to the left IFG or Cathodal tDCS to the left IFG)
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Floriana Costanzo
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT05147220
- Testing
- Remibrutinib, Teriflunomide
- Where
- 200 sites in United States, Argentina and 32 more
- Volunteers
- 1,000 people
- Sponsor
- Novartis Pharmaceuticals
Role of Neurofilment in Diagnosis of Multiple Sclerosis
Neurofilament Light Chain as Diagnostic and Prognostic Marker in naïve Multiple Sclerosis Patients
Neurofilament protein detected in the serum appears to be a good marker for the extent of active neurodegeneration. Chitinase may also be a good marker reflecting the degree of astrocyte activation, or damage in active lesions…
- Trial name
- NFLMS (NCT06197841)
- Where
- Egypt
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Assiut University
Anorexia Nervosa, Anorexia Nervosa Restricting Type
Novel Targetable BIOmarkers in ANorexia NervosA
The overall aim of this present study is to evaluate Growth Differentiation Factor-15 (GDF-15) and inflammatory cytokines as a possible novel and readily treatable target for the successful therapy of Anorexia Nervosa (AN).
- Trial name
- BIOANNA (NCT05885724)
- Where
- Switzerland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland